Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Tax Provisions (2020 - 2025)

Keros Therapeutics' Tax Provisions history spans 4 years, with the latest figure at -$1.5 million for Q4 2025.

  • For Q4 2025, Tax Provisions fell 604.67% year-over-year to -$1.5 million; the TTM value through Dec 2025 reached $4.9 million, up 1527.67%, while the annual FY2025 figure was $4.9 million, 1527.67% up from the prior year.
  • Tax Provisions reached -$1.5 million in Q4 2025 per KROS's latest filing, down from -$1.4 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $10.0 million in Q1 2025 to a low of -$2.2 million in Q2 2025.
  • Average Tax Provisions over 3 years is $899250.0, with a median of $6000.0 recorded in 2021.
  • Peak YoY movement for Tax Provisions: soared 129.07% in 2021, then tumbled 604.67% in 2025.
  • A 3-year view of Tax Provisions shows it stood at $2.0 million in 2021, then plummeted by 84.99% to $300000.0 in 2024, then crashed by 604.67% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Tax Provisions are -$1.5 million (Q4 2025), -$1.4 million (Q3 2025), and -$2.2 million (Q2 2025).